>>ASP4132

ASP4132

Catalog No.GC60058

ASP4132는 18nM의 EC50을 가진 경구 활성, 강력한 AMPK 활성제입니다. ASP4132는 항암 활성을 가지며 유방암 이종이식 마우스 모델에서 종양 퇴행을 만듭니다.

Products are for research use only. Not for human use. We do not sell to patients.

ASP4132 Chemical Structure

Cas No.: 1640294-30-9

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$239.00
재고 있음
5mg
US$139.00
재고 있음
10mg
US$232.00
재고 있음
25mg
US$417.00
재고 있음
50mg
US$695.00
재고 있음
100mg
US$1,159.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ASP4132 is an orally active, potent AMPK activator with an EC50 of 18 nM. ASP4132 has anti-cancer activity and makes tumor regression in breast cancer xenograft mouse models[1].

ASP4132 shows comparable cell growth inhibitory (IC50=0.014 μM) activity against MDA-MB-453 breast cancer cell[1]. ASP4132 shows relatively weak antiproliferative activity against SK-BR-3 (IC50>3 μM)[1].

ASP4132 (0.5-8 mg/kg; PO; once daily; for 21 days) causes the tumor growth inhibition and regression[1]. ASP4132 (1 mg/kg; IV or PO) has a T1/2 of 3.6 hours, a CLtot of 19 mL/min•kg, and a Vss of 4.6 L/kg for rats for IV[1]. ASP4132 is stable in human liver microsomes (HLM CLint, vitro=61 mL/min/kg)[1]. Animal Model: Five-week-old male nude mice with MDA-MB-453[1]

[1]. Kazuyuki Kuramoto, et al. Development of a Potent and Orally Active Activator of Adenosine Monophosphate-Activated Protein Kinase (AMPK), ASP4132, as a Clinical Candidate for the Treatment of Human Cancer. Bioorg Med Chem. 2020 Mar 1;28(5):115307.

리뷰

Review for ASP4132

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ASP4132

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.